EAU 2011 - Health-related quality of life after salvage high intensity focused ultrasound treatment (HIFU) for locally radiorecurrent prostate cancer - Session Highlights

VIENNA, AUSTRIA (UroToday.com) - The study goal was to evaluate health related quality of life (HRQOL) after salvage high intensity focused ultrasound (HIFU) for locally radio-recurrent prostate cancer (CaP). A total of 57 patients treated with salvage HIFU were given the UCLA Prostate Cancer Index (UCLA-PCI) questionnaire at baseline and at follow-up 3 months or later. Scores ranged from 0 (worst) to 100 (best). Clinically significant change was defined as a minimum difference of 10 points between baseline scores and the scores at follow-up. The SF-12 is a general HRQOL instrument, which is included in the UCLA-PCI questionnaire. The physical component summary (PCS-12) score and the mental component summary (MCS-12) score are calculated from SF-12 according to established algorithms. The mean score of PCS-12 and MCS-12 in the Norwegian general population is 50.


Forty-six patients (81%) were evaluable. The mean time lapse between HIFU treatment and the questionnaire response was 17.5 months. The mean score for urinary function decreased from 79.7 before HIFU to 67.4 after HIFU (p<0.001). Patients using 1-2 pads a day increased from 11% to 44% and patients using≥3 pads increased from 0% to 16% before and after HIFU, respectively (p<0.001). The mean score for sexual function decreased from 32.1 before HIFU to 17.2 after HIFU (p<0.001). Patients reporting intercourse in the previous 4 weeks decreased from 29% at baseline to 15% post-HIFU (p=0.1). The bowel and hormonal functions were not significantly affected. There was a statistically significant reduction in the mean score of PCS-12 score from 52.7 before HIFU to 50.4 after HIFU (p<0.001). The MSC score was not significantly changed. They concluded that the treatment of localized radio-recurrent CaP by salvage HIFU is associated with clinically significant reduction in urinary function. They found that the reduction of sexual function is of less significance.



Presented by Viktor Berge, MD, PhD, et al. at the 26th Annual European Association of Urology (EAU) Congress - March 18 - 21, 2011 - Austria Centre Vienna, Vienna, Austria


The opinions expressed in this article are those of the UroToday.com Contributing Medical Editor and do not necessarily reflect the viewpoints of the European Association of Urology (EAU)


View EAU 2011 Annual Meeting Coverage